BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy
verfasst von:
Kathryn J. Schlich-Bakker, Margreet G. E. M. Ausems, Maria Schipper, Herman F. J. ten Kroode, Carla C. Wárlám-Rodenhuis, Jan van den Bout
This study assessed psychological distress during the first year after diagnosis in breast cancer patients approached for genetic counseling at the start of adjuvant radiotherapy and identified those vulnerable to long-term high distress. Of the approached patients some chose to receive a DNA test result (n = 58), some were approached but did not fulfill criteria for referral (n = 118) and some declined counseling and/or testing (n = 44). The comparative group consisted of patients not eligible for genetic counseling (n = 182) and was therefore not approached. Patients actively approached for genetic counseling showed no more long-term distress than patients not eligible for such counseling. There were no differences between the subgroups of approached patients. Predictors for long-term high distress or an increase in distress over time were pre-existing high distress and a low quality of life, having children, and having no family members with breast cancer. It is concluded that breast cancer patients can be systematically screened and approached for genetic counseling during adjuvant radiotherapy without imposing extra psychological burden. Patients vulnerable to long-term high distress already displayed high distress shortly after diagnosis with no influence of their medical treatment on their level of distress at long-term.
Introduction
Breast cancer is among the most widely diagnosed cancers in the world with an estimated 1.15 million cases worldwide in 2002 [1]. The psychological effect of a breast cancer diagnosis and subsequent treatment is well documented, revealing high distress in 20–30% of breast cancer patients during the first year after diagnosis. The majority no longer experience serious psychological distress one year after surgery [2‐6]. Patient-related factors such as age, personality characteristics, previous psychological treatment, severely stressful non-cancer life experiences, pre-existing general health complaints, illness perceptions and postoperative distress are all related to long-term psychological distress. Objective cancer-related factors such as TNM-stage and type of local or adjuvant treatment do not influence psychological distress after diagnosis [3‐7].
An estimated 5–10% of all breast cancers may be accounted for by inherited autosomal dominant susceptibility genes [8] accompanied by an increased risk for a second breast and/or ovarian cancer [9]. Pre-symptomatic DNA testing in families with a BRCA mutation is associated with psychological benefits for non-carriers while, generally, no adverse psychological effects are observed amongst carriers [10]. However, some characteristics of applicants vulnerable to high distress have been identified including: high pre-test distress, carrier status, complicated grief, more affected first-degree relatives, and strong emotional illness representations [11, 12].
Anzeige
Among breast cancer patients diagnosed between 4 months and 32 years before undergoing genetic testing, those diagnosed within the year prior to testing were more anxious, reporting more breast-cancer-specific distress than those with more than one year between diagnosis and testing [13]. Affected mutation carriers, especially recently diagnosed patients, showed a stronger decline in psychological well-being than unaffected mutation carriers two weeks after the DNA result [14]. This potential negative impact was also reported by Bonadona et al. [15].
A systematic active approach of recently diagnosed breast cancer patients for BRCA1/2 mutation screening increases patients’ awareness of genetic issues and may positively influence the actual uptake for BRCA1/2 mutation searching. Consequently, breast cancer patients are included who might not have applied for genetic counseling on their own initiative and who might show less psychological resilience than the previously studied non-affected participants who applied on their own initiative [16]. The future role of genetic counseling and BRCA testing during the process of deciding on primary surgical treatment for breast cancer [17‐20] implies the time between diagnosis and genetic counseling and testing will only become shorter. Breast cancer patients will be approached for genetic counseling during the most stressful period of treatment, i.e. immediately after diagnosis.
Earlier we reported on the short-term psychological responses of breast cancer patients to an active approach for genetic counseling seven weeks after surgical treatment, at the beginning of their adjuvant radiotherapy [21]. We found no increase in psychological distress shortly after such an approach. Nor was there a difference in the level or course of psychological distress between patients approached for genetic counseling and those not eligible and therefore not approached. However, of all approached breast cancer patients, 50% showed high distress after approach. Approached patients vulnerable to short-term high distress were younger, single, less optimistic, experienced little social support, used an avoiding coping style and displayed a lower quality of life and higher distress level before approach for genetic counseling. To the best of our knowledge no studies have reported on the long-term effects of such a pro-active approach in such an early stage of treatment.
The aim of this study was to gain insight into the course of psychological distress during the year following breast cancer diagnosis in: (1) patients who receive a DNA-test result, (2) patients who initially take part in genetic counseling but who do not fulfill criteria for further counseling, and (3) patients who decline genetic counseling and/or testing. A second aim was to identify breast cancer patients vulnerable to long-term high distress after being approached for genetic counseling shortly after diagnosis.
Anzeige
According to a retrospective study among breast cancer patients who received their carrier status some 2 months to 10 years after their cancer diagnosis, the majority believed there was already an emotional overload in coping with the diagnosis and treatment, and that offering DNA testing shortly after learning they had cancer would have added too much additional stress [22]. The majority of health professionals were of the same opinion [22]. This report gave us reason to expect a higher long-term psychological distress among recently diagnosed breast cancer patients approached for genetic counseling and BRCA testing compared to patients not approached for counseling. We expected the same factors to influence long-term levels of distress as identified for short-term distress (see above) [21]. Additionally, we expected highly distressed patients to have more relatives with breast cancer [12, 23].
Patients and methods
Participants
Participants were breast cancer patients referred to the University Medical Centre Utrecht for adjuvant radiotherapy between January 2002 and March 2004. Inclusion criteria were: a first diagnosis of breast cancer, age between 18 and 75 years, and fluent in the Dutch language.
Procedure
The procedure used in our initial approach for genetic counseling has been described elsewhere [21]. Referred breast cancer patients were recruited for our psychological study prior to their first visit to the Department of Radiotherapy. During this first visit they were assessed for eligibility for genetic counseling using factors presumed predictive for hereditary breast cancer [21]. If patients were positive for at least one factor, they were actively approached to have a family pedigree drawn up ( = initial approach). If this revealed at least one criterion for further genetic counseling patients were referred to the Department of Medical Genetics for further counseling and BRCA 1/2 mutation testing. The criteria were: (1) breast cancer in patient or relative <40 years of age, (2) two or more relatives with breast cancer, (3) multifocal, multicentric or bilateral breast cancer in patient or relative with the first breast cancer diagnosed <50 years of age, (4) ovarian cancer in patient or relative, and (5) a male relative with breast cancer.
Patients completed questionnaires one week prior to approach for genetic counseling (T0), four weeks after initial approach (T1), three weeks after pedigree compilation (T2), three weeks after the first visit to the Department of Medical Genetics (T3), and three weeks after receiving DNA test results (T4) (Fig. 1). Questionnaires were returned by mail. All participants completed T0 and T1. Where the comparative group completed all five questionnaires, those approached for counseling only completed three questionnaires in total. The timing of the third questionnaire depended on when a patient left the genetic counseling protocol, either due to ineligibility for further counseling, after declining further counseling or after receiving a DNA test result. This study was approved by the Medical Ethics Committee of the University Medical Centre Utrecht.
Fig. 1
Study flow scheme
×
Measures
At baseline (T0) participants provided demographics (age, marital status, number of children, educational level and employment), information on family cases of breast cancer and on their involvement with cancer in relatives. The treating physician registered medical history including time since surgery, type of surgery (mastectomy vs. lumpectomy), extent of adjuvant therapy and TNM stage.
Participants completed the following psychological characteristics:
UtrechtCoping List (UCL) [24], a 15-item coping strategy scale evaluating active coping, social support seeking, avoidance and palliative reactions on a four-point frequency scale from ‘almost never’ to ‘nearly always’ (Cronbach’s alpha was 0.67–0.84 in a random selection of Dutch cancer patients).
The Optimism part of the Self-Assessment Questionnaire-Nijmegen (SAQ-N) [25, 26], an 8-item scale measuring the level of optimistic outlook on life on a four-point frequency scale ranging from ‘almost never’ to ‘nearly always’.
The Quality of Life part of the EORTC-QLQ [27], a 2-item subscale measuring general quality of life in cancer patients on a seven-point Likert scale.
A self-designed single item on social support, scoring whether patients have someone to share personal problems and feelings with (‘no’, ‘yes, with one person’, and ‘yes, with more than one person’).
At each measurement (T0 through T4) participants completed the following two outcome measures:
HospitalAnxiety and Depression Scale (HADS) [28], a 14-item scale measuring anxiety and depression (7 items each) with a total score ranging from 0 to 42. A total score >13 is considered indicative of adjustment disorder [29].
Impact of Event Scale (IES) [30], a 15-item scale measuring intrusion (7 items) and avoidance (8 items) geared towards breast cancer as the distressing event. A total score ≥26 is considered indicative of clinical adaptation difficulties [31, 32].
To identify vulnerable patients, the total HADS and IES scores at each measurement were dichotomized using the cut-off scores for high psychological distress (HADS > 13, IES ≥ 26). The development of both measures was identified for each patient, yielding four patterns: (1) patients scoring under the cut-off at baseline and at the last measurement (low group), (2) patients scoring under the cut-off at baseline and above the cut-off at the last measurement (increasing group), (3) patients scoring above the cut-off at baseline but drop below at the last measurement (decrease group), and (4) patients scoring above the cut-off at baseline and at the last measurement (high group). The high and increase groups were considered vulnerable.
Statistical analysis
Using mixed models in the statistical program R (version 2.1.0.) accounting for the multiple measurement of each individual patient and correcting for differences in medical history, we analyzed courses of psychological distress and whether distress depends on approach for genetic counseling and/or participation in DNA testing. Based on dichotomized baseline scores for psychological distress, the two low baseline groups and the two high baseline groups were compared on demographic characteristics, medical history and psychological measures with non-parametric tests using the Statistical Package for Social Sciences (SPSS 12.0). Differences in univariate variables were analyzed using the χ2-test on nominal variables and the Mann–Whitney test on continuous variables. To identify predictors for long-term high psychological distress, these variables were entered into a binary logistic regression model using a forward, stepwise, procedure model building strategy (Nagelkerke’s R2).
Results
Characteristics of the study groups
Of the 669 breast cancer patients recruited for this psychological study 473 (71%) returned the baseline questionnaire. Of the 473, 402 (85%) patients completed at least two measurements and were included in the study; 348 (74%) patients completed all measurements. Figure 1 shows participant details divided into four groups. Fifty-eight patients received a DNA test result (DNA test group), while the pedigree analyses showed 118 patients did not meet criteria for further counseling (No referral group). Patients who declined genetic counseling at any time were grouped into the Decline group (n = 44). One hundred and eighty-two patients were not eligible for genetic counseling and were therefore not approached (Comparative group). Differences between the total group approached and the comparative group have been described elsewhere [21]. Table 1 gives the demographic characteristics and medical history of the four groups.
Table 1
Demographic and medical characteristics of breast cancer patients who received a DNA-test result, patients who were not eligible for further counseling, patients who declined genetic counseling, and the comparative group
DNA-test (1) (n = 58)
No referral (2) (n = 118)
Decline (3) (n = 44)
Comparative (4) (n = 182)
χ2
p
Sign. differences
Demographics
Age, mean (range)
45 (24–70)
55 (41–74)
49 (28–72)
57 (40–74)
54.672
0.000*
1–2, 1–4, 3–2, 3–4
With partner (%)
80.7
76.1
81.8
74.2
1.655
0.648
With children (%)
86.2
82.9
70.5
82.3
4.359
0.222
Education ≥ high school (%)
49.1
41.0
59.1
29.7
16.706
0.001*
3–4
Employed at diagnosis (%)
73.7
58.1
59.1
44.5
16.920
0.001*
1–4
Medical history
Days post operation, mean (range)
58.4 (21–201)
55 (19–153)
48 (13–141)
56 (9–182)
2.068
0.558
Mastectomy (%)
27.6
15.4
20.5
19.6
9.668
0.020*
1–4
Adjuvant treatment
None (%)
46.6
57.3
45.5
70.3
16.779
0.001*
4–1, 4–3
Chemo prior to RT (%)
13.8
6.8
18.2
4.4
11.487
0.007*
4–3
Chemo after RT (%)
12.1
10.3
9.1
3.8
7.374
0.054
Hormone (%)
27.6
25.6
27.3
21.4
1.639
0.656
pN stage
0
43.1
56.9
53.5
65.3
9.564
0.022*
1–4
1
50.0
40.5
44.2
33.5
5.779
0.123
2
5.2
0.9
2.3
–
8.254
0.009*
1–4
3
1.7
1.7
–
1.1
0.942
0.921
Family history bc
None (%)
38.6
21.6
30.2
92.3
193.161
0.000*
4–1, 4–2, 4–3
Only FDR bc (%)
21.1
22.4
27.9
1.1
52.643
0.000*
4–1, 4–2, 4–3
Only SDR bc (%)
24.6
42.2
37.2
6.0
63.727
0.000*
4–1, 4–2, 4–3
FDR + SDR (%)
15.8
13.8
4.7
0.5
29.947
0.000*
4–1, 4–2
Involvement cancer in family (%)
33.9
37.6
25.0
28.5
3.727
0.291
* Significant difference p < 0.05; RT = radiotherapy, FDR = first degree relative, SDR = second degree relative, bc = breast cancer, employed = employed outside the home upon diagnosis, pN stage = pathologic regional lymph node stage according to the UICC TNM classification of malignant tumors, fifth edition
Anzeige
Level and course of psychological distress
The four groups did not differ in level or course of general anxiety and depression or breast-cancer-specific distress. Nor did they differ in the percentage of patients scoring above the cut-off scores for high anxiety and depression or severe adaptation difficulties. Originally the model was corrected for differences in medical history between the four groups. However, no effect was identified proving a simplified model as sufficient for the investigation of the level and course of distress over time. The course of psychological distress in all four groups fits a curvi-linear model, decreasing after the initial approach up to week 27, followed by a small increase up to week 43 (Figs. 2 and 3). The models that best fit the course of distress were:
9.3314 −0.1251 * time + 0.0027 * time2 for anxiety and depression (C.I. time −0.1745 to −0.0757, p = 0.000 and C.I. time2 0.0015–0.0038, p = 0.000) and
Fig. 2
Fitted model for the course of the total HADS score measured one week prior to approach and 4, 11, 27 and approximately 43 weeks after approach for genetic counseling
Fig. 3
Fitted model for the course of the total IES score measured 1 week prior to approach and 4, 11, 27 and approximately 43 weeks after approach for genetic counseling
×
×
25.6297 − 0.3457 * time + 0.0067 * time2 for breast-cancer-specific distress (C.I. time −0.4443 to −0.2471, p = 0.000 and C.I. time2 0.0044–0.0090, p = 0.000).
Predictors for pattern of psychological distress
Anxiety and depression (HADS)
Total baseline scores of anxiety and depression show a Pearson correlation of 0.72 with total scores on the last measurement. A pattern of anxiety and depression was obtained for 215 of the 220 approached patients. The four patterns did not differ on demographic characteristics or medical history. Compared to the HADS low group, the HADS increase group had a more avoiding coping style (Z = −2.718, p = 0.006) and reported lower quality of life (Z = −3.056, p = 0.002), more anxiety and depression (Z = −4.231, p = 0.000) and more breast-cancer-specific distress (Z = −2.777, p = 0.005) at baseline. The baseline level of anxiety and depression was the only predictor for an increase in anxiety and depression at the last measurement (O.R. 1.416, C.I. 1.180–1.700, Table 2).
Table 2
Significant predictors for long-term high psychological distress: forward stepwise binary logistic regression model
χ2
P
R2
Increase R2
N = 215
HADS low n = 134 (62.3%)
HADS increase n = 24 (11.2%)
Step 1 High HADS baseline
18.292
0.000
0.215
HADS decrease n = 24 (11.2%)
HADS high n = 33 (15.3%)
Step 1 Low QL baseline
11.891
0.001
0.291
Step 2 Having children
5.065
0.024
0.395
0.104
N = 214
IES low n = 87 (40.7%)
IES increase n = 12 (5.6%)
Step 1 High IES baseline
8.422
0.004
0.183
IES decrease n = 35 (16.4%)
IES high n = 80 (37.4%)
Step 1 High HADS baseline
18.745
0.000
0.242
Step 2 No family history bc
10.940
0.012
0.364
0.122
Only FDR
0.339
Only SDR
0.006
FDR + SDR
0.057
QL = Quality of life, FDR = first degree relative, SDR = second degree relative, bc = breast cancer
At baseline the HADS high group was less optimistic (Z = −2.150, p = 0.031), experienced a lower quality of life (Z = −3.272, p = 0.001) and reported more anxiety and depression (Z = −2.710, p = 0.006) than the HADS decrease group. A high pattern of anxiety and depression was best predicted by lower perceived quality of life at baseline (O.R. 0.912, C.I. 1.180–1.700) and having children (O.R. 0.125, C.I. 0.018–0.863, Table 2).
Breast-cancer-specific distress (IES)
Total baseline scores and last scores on breast-cancer-specific distress showed a Pearson correlation of 0.56. A pattern for breast-cancer-specific distress was obtained for 214 approached patients. There were no differences between the four patterns on demographics or medical history. Compared to the IES low group, the IES increase group demonstrated a more avoiding coping style (Z = −2.011, p = 0.044) and a higher anxiety and depression (Z = −2.063, p = 0.038) and breast-cancer-specific distress (Z = −3.130, p = 0.001) at baseline. An increase in breast-cancer-specific distress was predicted by the level of breast-cancer-specific distress at baseline (O.R. 1.181, C.I. 1.034–1.348, Table 2).
The IES high group reported more anxiety and depression (Z = −3.400, p = 0.001) and breast-cancer-specific distress (Z = −2.562, p = 0.010) at baseline than the IES decrease group. In addition, the IES high group more often had no breast cancer in the family (χ2 = 7.607, p = 0.009) and less often only second-degree relatives with breast cancer (χ2 = 9.836, p = 0.003). A high pattern of breast-cancer-specific distress was predicted firstly by high anxiety and depression at baseline (O.R. 1.222, C.I. 1.096–1.363), followed by having no family members with breast cancer, rather than only second-degree affected relatives (O.R. 2.680, C.I. 0.462–15.548) or both first- and second-degree relatives (O.R. 0.773, C.I. 0.167–3.588) (Table 2).
Discussion
Contrary to our expectations there was no adverse effect from actively approaching recently diagnosed breast cancer patients for genetic counseling or from their participation in counseling and DNA testing during primary treatment. Long-term psychological distress scales showed no differences in either of our groups’ level or course of psychological distress during the year following diagnosis. The hesitance of health professionals to approach breast cancer patients for genetic testing during primary treatment [22] thus seems unwarranted, even though recently diagnosed patients experience more distress during genetic counseling and testing than patients diagnosed earlier [13]. Perhaps the possibly hereditary nature of their cancer is not as distressing as the diagnosis of breast cancer itself [33].
The possibility of a ceiling effect in distress after diagnosis is not a valid explanation for the absence of adverse effect since there was an increase in distress among a subgroup of patients. This subgroup consisted mainly of patients who reported higher levels of distress prior to approach and included patients not referred for further counseling, patients who declined counseling at some point and some who received a DNA test result.
The curvi-linear course of psychological distress in all groups may relate to primary treatment for breast cancer combined with decreasing distress simply due to passing of time [31]. Highest distress was noted close to diagnosis and surgery, decreasing during adjuvant treatment and reaching the lowest point at the end of radiation therapy. Anticipation of the annual mammogram and fear of a possible recurrence or second breast cancer may account for the small increase towards the end of the first year after diagnosis [34].
Anzeige
Considering earlier findings among breast cancer patients, the present study supports psychological distress at baseline as main predictor for later distress [5, 6] and the absence of influence of breast cancer medical treatment [3, 4, 6, 7], including approach for genetic counseling. However, our study does not confirm age, marital status and level of optimism as relevant for long-term distress [4, 7, 21].
Of the short-term psychological distress predictors [21], only the reported quality of life prior to approach continued to play a role in the prediction of long-term distress. We identified new factors such as having children or having no relatives with breast cancer. The role of having children in long-term psychological distress is consistent with other findings [20]. It is possible that during primary treatment patients are overwhelmed by distress of their diagnosis and that only after completing primary treatment do they begin to worry about the implications for their children thus making this a more important and longer-term cause of distress.
The finding that patients with high baseline distress and no relatives with breast cancer are more likely to remain highly distressed does not confirm findings by Van Oostrom et al. [12] among healthy applicants from families with known BRCA1/2 mutations. Besides negative experiences of breast cancer in the family (e.g. extensive treatment or loss of a family member), positive experiences during course of treatment may occur yielding positive effects on psychological distress. The subgroup of patients with high baseline distress and no relatives with breast cancer lack these experiences and therefore this potentially positive effect.
In summary, our study suggests that breast cancer patients can be approached for genetic counseling at the beginning of adjuvant radiotherapy and undergo genetic testing without adding an extra psychological burden. It should be noted that our findings pertain solely to the affected proband. We did not study effects of diagnosis and consecutive genetic testing on family members. Nor did we describe in the current write up the effects on the partners of newly diagnosed patients. Additionally, although patients were approached shortly after diagnosis, genetic counseling and testing took approximately six months to complete. Receiving a DNA result within three to six weeks, as in true rapid testing, may affect the level and course of patients’ distress differently. Another limitation was the absence of a true experimental design since the comparative group comprises patients ineligible for genetic counseling and thus not approached.
Anzeige
Based on the present results, clinicians should preferably have knowledge of patients’ psychological distress and their perceived quality of life before approaching them for genetic counseling in order to provide adequate support if needed. Assessment should preferably take place using standardized questionnaires, so results can be easily compared to norms. Family history of breast cancer and whether a patient has children should also be noted.
Early detection of BRCA1/2 mutations is playing an increasing role in decisions about surgical treatment [16, 19]. Patients suspected of hereditary breast cancer who have not reached a decision about definite local treatment may benefit from immediate genetic referral [17]. We have shown that systematic screening with an active approach and participation in genetic testing during adjuvant radiotherapy does not influence patients’ levels of distress long-term. The next question is what the psychological impact is of having genetic counseling and rapid BRCA results before making surgical decisions.
Acknowledgements
Special thanks are in order to all the participating patients and radiation oncologists from the Department of Radiotherapy at the University Medical Centre Utrecht, the Netherlands. We also thank Jeanne van Echtelt for asking all the patients to participate in the study and further monitoring their participation and Jackie Senior and David Alexander for critically reading the manuscript. The Dutch Cancer Society supported this work, grant no. UU 2001–2386.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 2.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Mit e.Med Gynäkologie erhalten Sie Zugang zu CME-Fortbildungen der beiden Fachgebiete, den Premium-Inhalten der Fachzeitschriften, inklusive einer gedruckten gynäkologischen oder urologischen Zeitschrift Ihrer Wahl.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
